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Abstract
Anaphylaxis is an acute, potentially fatal systemic reaction with varied mechanisms and clinical presentations.
Although prompt recognition and treatment of anaphylaxis are imperative, both patients and healthcare
professionals often fail to recognize and diagnose early signs and symptoms of the condition. Clinical
manifestations vary widely, however, the most common signs are cutaneous symptoms, including angioedema,
urticaria, erythema and pruritus. Immediate intramuscular administration of epinephrine into the lateral thigh is
first-line therapy, even if the diagnosis is uncertain. The mainstays of long-term management include specialist
assessment, avoidance measures, and the provision of an epinephrine auto-injector and an individualized
anaphylaxis action plan. This article provides an overview of the causes, clinical features, diagnosis and acute and
long-term management of this serious allergic reaction.
Introduction
Anaphylaxis is defined as a serious allergic reaction that
is rapid in onset and may cause death [1,2]. The preva-
lence of anaphylaxis is estimated to be as high as 2%,
and appears to be rising, particularly in the younger age
group [3-5].
The more rapidly anaphylaxis develops, the more
l i k e l yt h er e a c t i o ni st ob es e v e r ea n dl i f e - t h r e a t e n i n g
[4]. Therefore, prompt recognition and management of
the condition are imperative. However, anaphylaxis is
often under-recognized and treated inadequately. Diag-
nosis and management are challenging since reactions
are often immediate and unexpected. Furthermore,
there is no single test to diagnose anaphylaxis in routine
clinical practice [3,6]. This article will provide an over-
view of the causes and clinical features of anaphylaxis as
well as strategies for the accurate diagnosis and manage-
ment of the condition.
Causes
Most episodes of anaphylaxis are triggered through an
immunologic mechanism involving immunoglobulin E
(IgE) which leads to mast cell and basophil activation
and the subsequent release of inflammatory mediators
such as histamine, leukotrienes, tryptase and prostaglan-
dins. Although any substance has the potential to cause
anaphylaxis, the most commonc a u s e so fI g E - m e d i a t e d
anaphylaxis are: foods, particularly, peanuts, tree nuts,
shellfish and fish, cow’sm i l k ,e g g sa n dw h e a t ;m e d i c a -
tions (most commonly penicillin), and natural rubber
latex. Exercise, aspirin, non-steroidal anti-inflammatory
drugs (NSAIDs), opiates, and radiocontrast agents can
also cause anaphylaxis, but anaphylactic reactions to
these agents often result from non-IgE-mediated
mechanisms. In other cases, the cause of anaphylactic
reactions is unknown (idiopathic anaphylaxis). In chil-
dren, anaphylaxis is most often caused by foods, while
venom- and drug-induced anaphylaxis is more common
in adults [4,7-9]. Table 1 provides a more comprehen-
sive list of the potential causes of anaphylaxis.
Co-morbidities and concurrent medications may also
affect the severity of anaphylactic reactions and patient
response to treatment. For example, patients with
asthma and cardiovascular disease are more likely to
experience a poor outcome from anaphylaxis. Concur-
rent administration of beta-blockers can interfere with
the patient’s ability to respond to epinephrine, the first-
line of treatment for anaphylaxis (discussed later).
Furthermore, the use of angiotensin-converting enzyme
(ACE) inhibitors and angiotensin receptor blockers
(ARBs) can impact a patient’s compensatory physiologic
response to anaphylaxis, leading to more severe reac-
tions [10].
Signs and symptoms
Since anaphylaxis is a generalized reaction, a wide vari-
ety of clinical signs and symptoms involving the skin,
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system can be observed (see Table 2). The most common
clinical manifestations are cutaneous symptoms, including
urticaria and angioedema, erythema (flushing), and pruri-
tus (itching) [11]. Patients also often describe an impend-
ing sense of death (angor animi). Death due to
anaphylaxis usually occurs as a result of respiratory
obstruction or cardiovascular collapse, or both. Evidence
suggests that there is a direct correlation between the
immediacy of symptom onset and the severity of the epi-
sode, with the more rapid the onset, the more severe the
event [12]. It is important to note that the signs and symp-
toms of anaphylaxis are unpredictable and may vary from
patient to patient and from one reaction to another.
Therefore, the absence of one or more of the common
symptoms listed in Table 2 does not rule out anaphylaxis,
and should not delay immediate treatment.
The signs and symptoms of anaphylaxis typically
develop within minutes after exposure to the offending
antigen, but may occasionally occur as late as 1 hour
post exposure. Symptoms usually follow a uniphasic
course, with resolution of symptoms within hours of
treatment. However, up to 20% of reactions follow a
biphasic course characterized by an asymptomatic per-
iod of 1-8 hours followed by recurrent symptoms [13].
Diagnosis
The diagnosis of anaphylaxis is based primarily on
clinical signs and symptom s ,a sw e l la sad e t a i l e d
description of the acute episode, including antecedent
activities and events. Diagnostic criteria for anaphylaxis
were published by a multidisciplinary group of experts
in 2005 and 2006, and are shown in Table 3[1,2]. A
diagnosis of anaphylaxis is highly likely when any one
of the criteria listed in Table 3 is fulfilled. Since the
evaluation and diagnosis of anaphylaxis is often com-
plex, referral to an allergist with training and expertise
in the identification and management of anaphylaxis
should be considered.
History
The history is the most important tool to establish the
cause of anaphylaxis and should take precedence over
diagnostic tests. It should elicit information about clini-
cal manifestations (e.g., urticaria, angioedema, flushing,
pruritus, airway obstruction, gastrointestinal symptoms,
syncope, and hypotension); agents encountered before
the reaction, such as foods, medications or insect bites/
stings, as well as the patient’s activities preceding the
event (e.g., exercise, sexual activity). The absence of
cutaneous symptoms puts the diagnosis in question
since the majority of anaphylactic episodes include
Table 1 Causes of anaphylaxis
Common:
￿ Foods: most commonly peanuts, tree nuts, egg, seafood and fish,
cow’s milk, wheat
￿ Medications: most commonly antibiotics
￿ Insect stings (bees and wasps)
￿ Natural rubber latex
￿ Unidentified (no cause found; idiopathic anaphylaxis)
Less common:
￿ Exercise
￿ Semen
￿ Food additives: monosodium glutamate, metabisulfite
￿ Hormonal changes: menstrual factors
￿ Topical medications
￿ Transfusions
Table 2 Signs and symptoms of anaphylaxis [6,11]
Skin
￿ Urticaria (hives)
￿ Angioedema (swelling)
￿ Erythema (flushing)
￿ Pruritus (itching)
Gastrointestinal:
￿ Nausea
￿ Vomiting
￿ Abdominal pain
￿ Diarrhea
Respiratory:
￿ Upper airway:
– Nasal congestion
– Sneezing
– Hoarseness
– Cough
– Oropharyngeal or laryngeal edema
Neurologic:
￿ Light-headedness
￿ Dizziness
￿ Confusion
￿ Lower airway: dyspnea
– Bronchospasms
– Wheezing
– Chest tightness
Oral:
￿ Itching
￿ Tingling or swelling of the lips, tongue or palate
Cardiovascular:
￿ Hypotension
￿ Dizziness
￿ Syncope
￿ Tachycardia
Other:
￿ Sense of impending doom
￿ Anxiety
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rule out anaphylaxis [4].
Additional diagnostic tests
The diagnosis of a specific cause of anaphylaxis may be
supported by the results of skin tests and/or in vitro
IgE tests [4]. These tests can determine the presence
of specific IgE antibodies to foods, medications (e.g.,
penicillin), and stinging insects. However, for the
majority of medications, standardized skin tests and/or
in vitro tests are not available. In general, skin testing
is more sensitive than in vitro testing and is the diag-
nostic procedure of choice for the evaluation of most
IgE-mediated causes of anaphylaxis (if available for the
relevant trigger or allergen). If skin testing is per-
f o r m e d ,i ts h o u l db ed o n eu n d e rt h es u p e r v i s i o no fa
physician who is experienced in the procedure in a set-
ting with appropriate rescue equipment and medica-
tion available [4].
The clinical diagnosis of anaphylaxis can sometimes
be supported by the documentation of elevated concen-
trations of mast cell and basophil mediators such as
plasma histamine or serum or plasma total tryptase.
However, it is critical to obtain blood samples for these
measurements as soon as possible after the onset of
symptoms since elevations are transient.
Differential diagnosis
Other diagnoses that might present with signs and/or
symptoms characteristic of anaphylaxis should be
excluded. The most common conditions that mimic
anaphylaxis include: vasodepressor (vasovagal/neurocar-
diogenic) reactions (which are characterized by hypoten-
sion, pallor, bradycardia, weakness, nausea and
vomiting); acute respiratory decompensation from severe
asthma attacks, foreign body aspiration and pulmonary
embolism; vocal cord dysfunction; acute anxiety (e.g.,
panic attack or hyperventilation syndrome); myocardial
dysfunction, acute poisoning; hypoglycemia; and seizure
disorders [4,14].
Treatment
Acute management
The acute treatment of anaphylaxis begins with rapid
assessment of the airway, breathing and circulation. Epi-
nephrine is the drug of choice for anaphylaxis and
should be given immediately to any patient with a sus-
pected anaphylactic episode. Treatment should be pro-
vided even if the diagnosis is uncertain since there here
are no contraindications to the use of epinephrine [6].
The recommended dosing of epinephrine for the acute
treatment of anaphylaxis is 0.01 mg/kg up to a maxi-
mum of 0.5 mg administered intramuscularly every 5–
20 min as necessary [6]. Intramuscular administration
into the lateral thigh is recommended as it allows for
more rapid absorption and higher plasma epinephrine
levels compared to subcutaneous administration [10].
Glucagon should also be considered in patients using
beta-blockers.
All patients receiving emergency epinephrine must be
transported to hospital immediately (ideally by ambu-
lance) for evaluation and observation. Patients should
also be placed in a recumbent (supine) position with the
lower extremities elevated, unless this is precluded by
shortness of breath or vomiting [6,15,16].
As mentioned earlier, patients with asthma, particu-
larly those with poorly controlled asthma, are at
increased risk of a fatal reaction. In these patients, ana-
phylaxis may be mistaken for an asthma exacerbation
and inappropriately treated solely with asthma inhalers.
Therefore, if there are ongoing asthma symptoms in an
individual with known anaphylaxis, epinephrine should
be given [6].
Oxygen therapy should also be considered in any
patient with symptoms of anaphylaxis, particularly for
those with prolonged reactions. Intravenous fluids
Table 3 Clinical criteria for diagnosing anaphylaxis [1,2]
Anaphylaxis is highly likely when any 1 of the following 3 criteria is fulfilled following exposure to an allergen:
1 Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives,
pruritus or flushing, swollen lips-tongue-uvula) and at least 1 of the following:
a. Respiratory compromise (e.g. dyspnea, wheeze, bronchospasm, stridor, reduced PEF, hypoxemia)
b. Reduced BP or associated symptoms of end-organ dysfunction (e.g. hypotonia [collapse], syncope, incontinence)
2 2 or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to several hours):
a. Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush, swollen lips-tongue-uvula)
b. Respiratory compromise (e.g., dyspnea, wheeze, bronchospasm, stridor, reduced PEF, hypoxemia)
c. Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope, incontinence)
d. Persistent GI symptoms (e.g., painful abdominal cramps, vomiting)
3 Reduced BP after exposure to a known allergen for that patient (minutes to several hours):
a. Infants and children: low systolic BP (age specific) or > 30% decrease in systolic BP
*
b. Adults: systolic BP < 90 mmHg or > 30% decrease from that person’s baseline
PEF = Peak expiratory flow; BP: blood pressure; GI: gastrointestinal
* Low systolic blood pressure for children is age specific and defined as: < 70 mmHg for age 1 month to 1 year; < 70mmHg + [2 x age] for age 1 to 10 years; <
90mmHg for age 11 to 17 years.
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should also be provided since massive fluid shifts can
occur rapidly in anaphylaxis due to increased vascular
permeability. Volume replacement is particularly impor-
tant for patients whose hypotension persists despite epi-
nephrine injections. Supportive therapy such as inhaled
beta2-agonists (for patients experiencing bronchospasm)
and antihistamines (for control of cutaneous symptoms)
can also be helpful, but should never replace epinephr-
ine as first-line therapy. Vasopressors, such as dopa-
mine, can also be considered if epinephrine injections
and volume expansion with intravenous fluids fail to
alleviate hypotension. Glucocorticosteroids have a slow
onset of action and, therefore, these agents have not
been shown to be effective for the acute treatment of
anaphylaxis. Theoretically, however, they may prevent
biphasic or protracted reactions and, hence, are often
given on an empirical basis. To date, there is no conclu-
sive evidence that the administration of glucocorticos-
teroids prevents a biphasic response [4].
If intramuscular epinephrine and intravenous fluids
fail to improve anaphylactic symptoms, intravenous
infusions of epinephrine may be required; however,
these infusions should be given by a physician who is
trained and experienced in its use and has the capacity
for continuous blood pressure and cardiac monitoring.
Figure 1 provides a simplified algorithm for the acute
management of anaphylaxis.
Following acute treatment, patients should be
observed for a period of time due to the risk of a bipha-
s i cr e s p o n s eo rp o s s i b l er e c u r r e n c eo ft h er e a c t i o na s
epinephrine wears off. The observation period should be
individualized based on the severity of the initial reac-
tion and access to care. Experts have recommended
observing patients for 4 to 6 hours following an anaphy-
lactic reaction, with prolonged observation times for
patients with severe or refractory symptoms [6].
Long-term management
The mainstays of long-term management for patients
who have experienced an anaphylactic episode include:
specialist assessment, a prescription for an epinephrine
auto-injector, patient and caregiver education on avoid-
ance measures, and the provision of an individualized
anaphylaxis action plan.
Specialist assessment
After acute anaphylaxis, patients should be assessed for
their future risk of anaphylaxis, ideally by an allergist.
These specialists are experienced in identifying and con-
firming the cause of anaphylaxis, educating patients on
appropriate avoidance strategies, drafting an anaphylaxis
action plan, and advising whether immunotherapy is
appropriate [4,6].
Prescription for an epinephrine auto-injector
A prescription for an epinephrine auto-injector should
be provided to all patients who have experienced ana-
phylaxis previously, including those who have had any
rapid-onset systemic allergic reaction (gastrointestinal,
respiratory, cardiac); diffuse hives to any food or insect
stings; or any rapid-onset (i.e., minutes to hours) reac-
tion of any severity to the highest risk foods such as
peanut, tree nuts, fish, and shellfish [6].
There are currently two epinephrine auto-injectors
available in North America: EpiPen
® and Twinject
®.
Both products come in two dosages (0.15 mg and 0.30
mg), which are prescribed according to weight. The
0.30 mg dosage should be used for those weighing 30
kg or more, and the 0.15 mg dosage for children
weighing between 15–30 kg. Certain sources recom-
mend switching to the 0.30 mg dose at 25 kg rather
than 30 kg [16]. These devices should be stored prop-
erly (avoiding temperature extremes) and replaced
before the expiration date. More information on these
auto-injectors is available at http://www.epipen.ca and
http://www.twinject.ca.
Upon prescription of an epinephrine auto-injector,
healthcare providers must instruct the patient on how
and when to use the device. Instructions on proper use
should be reviewed verbally and accompanied by a DVD
and/or written material, and should be reinforced
annually.
Education on avoidance measures
Patients and their caregivers should be educated about
agents or exposures that may place them at risk for
future reactions, and should be counselled on avoidance
measures that may be used to reduce the risk for such
exposures. Avoidance strategies should be individua-
lized, taking into consideration factors such as relevant
triggers, age, activity, occupation, hobbies, residential
conditions, access to medical care, and the patient’s
level of personal anxiety. Individuals who have had ana-
phylactic reactions to foods should be instructed to read
food labels carefully, watching for hidden ingredients
such as “natural flavour” or “spices” that may indicate
the presence of allergens (e.g., peanut, tree nuts, milk,
egg, shellfish, fish, sesame, soy and wheat), as well as
“may contain” warnings [4]. Recent evidence suggests
that peanut allergic children can be desensitized to pea-
nut by feeding them increasing amounts of peanut
under close supervision [17]. Similar results have been
noted for egg and milk allergy. Although these results
are promising, further confirmatory studies in this area
are needed before routinely recommending desensitiza-
tion procedures to patients with these food allergies (for
more information, see article on Food Allergy in this
supplement).
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informed about all cross-reacting medications that
should be avoided. Should there be a future essential
indication for use of the medication causing anaphy-
lactic reactions, it may be helpful to educate patients
about possible management options, such as medica-
tion pretreatment and use of low osmolarity agents in
patients with a history of reactions to radiographic
contrast media, or induction of drug tolerance proce-
dures (also known as drug desensitization) [4].
Induction of drug tolerance procedures temporarily
modify a patient’s immunologic or non-immunologic
response to a drug through the administration of
incremental doses of the drug. However, drug toler-
ance is usually maintained only as long as the drug is
administered; therefore, the procedure needs to be
repeated in the future if the patient requires the drug
again after finishing a prior therapeutic course (for
more information, see article on Drug Allergy in this
supplement).
No improvement
Assess ABC: Airway, Breathing, Circulation 
x Call 911 for immediate transfer to 
hospital
x Lie patient flat and raise patient’s 
legs (if breathing not impaired)
Anaphylaxis?
Oxygen and IV fluids Supportive therapy:
x Inhaled beta2-agonists (for 
bronchospasms)
x Antihistamines (for 
cutaneous symptoms)
x Vasopressors
x Glucocorticosteroids
IV epinephrine*
Intramuscular epinephrine
x 0.01 mg/kg up to a maximum of 0.5 mg 
x Repeat every 5–20 min if needed
Figure 1 Simplified algorithm for the acute management of anaphylaxis. IV: intravenous *Should be given by a physician trained in the use
of IV epinephrine with capacity for continuous blood pressure and cardiac monitoring
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insect sting should be advised about avoidance measures
to reduce the risk of future stings. Such measures
include: being alert when eating outdoors (as wasps are
attracted to food), wearing shoes and long pants when
in fields, and having nests or hives near the patient’s
home removed [14]. Patients who have previously
experienced venom-induced anaphylaxis are often candi-
dates for venom immunotherapy, which is successful in
preventing anaphylaxis in up to 98% of patients (see
article on Allergen Immunotherapy in this supplement).
Subjects at high risk of a reaction to latex include:
healthcare workers, children with spina bifida and geni-
tourinary abnormalities; and workers with occupational
exposure to latex. Patients with spina bifida (regardless
of a history of latex allergy) and patients with a positive
history of latex allergy should have all medical-surgical-
dental procedures performed in a latex-safe environ-
ment. This is an environment in which no natural rub-
ber latex gloves are used in the room or surgical suite
and in which there are limited latex-based accessories
(catheters, adhesives, tourniquets, anesthesia equipment
or devices) which come in contact with the patient [4].
Patients should also obtain and wear medical identifica-
tion (such as a MedicAlert bracelet/necklace) that indi-
cates that they have experienced anaphylaxis as well as the
responsible agent. Patients should also be instructed to
avoid drugs that might increase their susceptibility and/or
complicate the management of an anaphylactic event,
such as beta-blockers, ACE inhibitors, or ARBs [4].
Anaphylaxis action plan
A comprehensive, individualized anaphylaxis action plan
should be prepared which defines roles and responsibilities
and emergency protocols [6]. Important information that
should be included in this plan is shown in Table 4[6,18].
Examples of such a plan, along with other relevant infor-
mation and materials, can be downloaded at Anaphylaxis
Canada (http://www.anaphylaxis.ca) or the Food Allergy
and Anaphylaxis Network (http://www.foodallergy.org; a
US-based association). Action plans should be reviewed
annually and updated if necessary. A copy of the plan
should be made available to all relevant persons, such as
day-care providers, teachers, and employers. Recommen-
dations for the management of anaphylaxis in schools and
other community settings [15] are available through the
Allergy Safe Communities website at http://www.allergysa-
fecommunities.ca.
Conclusions
Anaphylaxis is an acute, potentially fatal systemic reac-
tion with varied mechanisms and clinical presentations.
Prompt recognition and treatment of anaphylaxis are
imperative; however, both patients and healthcare pro-
fessionals often fail to recognize and diagnose anaphy-
laxis in its early stages. Diagnostic criteria which take
into account the variable clinical manifestations of ana-
phylaxis are now available and can assist healthcare pro-
viders in the early recognition of the condition.
Immediate intramuscular administration of epinephrine
into the lateral thigh is first-line therapy for anaphylaxis.
Acute management may also involve oxygen therapy,
intravenous fluids, and adjunctive therapies such as anti-
histamines or inhaled beta2-agonists. The mainstays of
long-term management include specialist assessment, a
prescription for an epinephrine auto-injector, patient
and caregiver education on avoidance measures, and the
provision of an individualized anaphylaxis action plan.
Table 4 Components of an anaphylaxis action plan [6,18]
Contact details
￿ Names and contact details for emergencies, including family members, allergist/immunologist and family doctor
￿ Contact details for local emergency or ambulance services
Allergens/Triggers
￿ Clear identification of allergens/triggers to be avoided
– Include generic and proprietary names of drugs and possible cross-sensitivities, if relevant
How to recognize the signs and symptoms of anaphylaxis
￿ Mouth: itching, swelling of lips/tongue
￿ Throat: itching, tightness, closure, hoarseness
￿ Skin: itching, hives, eczema, swelling, flushing
￿ Gut: vomiting, diarrhea, abdominal pain
￿ Lung: shortness of breath, cough, wheeze
￿ Heart: hypotension, dizziness, syncope, tachycardia
￿ Neuro (or head): light-headedness
￿ Other: feeling of impending doom, anxiety
Medications prescribed and when they should be used
￿ Epinephrine auto-injectors (first-line); should include detailed instructions (with photographs, if possible) on how to correctly administer
the auto-injector device (for daycare, school and/or office staff)
￿ Antihistamines (for cutaneous symptoms)
￿ Inhaled beta2-agonists (for bronchospasm)
Where medication is stored at home, work or school
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￿ Anaphylaxis is defined as a serious allergic reaction
that is rapid in onset and may cause death.
￿ Prompt recognition and treatment are critical in
anaphylaxis.
￿ The diagnosis is based primarily on clinical signs
and symptoms.
￿ The most common clinical manifestations are cuta-
neous symptoms, including urticaria and angioedema,
erythema, and pruritus.
￿ Referral to an allergist or immunologist should be
considered for all persons who have experienced a pre-
vious anaphylactic episode.
￿ Epinephrine is the drug of choice for anaphylaxis
and should be given immediately, even if the diagnosis
is uncertain; intramuscular administration into the lat-
eral thigh is recommended.
￿ There are no contraindications to the use of
epinephrine.
￿ The mainstays of long-term treatment include: spe-
cialist assessment, avoidance measures, and the provi-
sion of an epinephrine auto-injector and an
individualized anaphylaxis action plan.
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